Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer

Japanese Journal of Clinical Oncology

Volumn 41, Issue 8, 2011, Pages 1013-1016

  Furugen, Makoto ^a,b   Sekine, Ikuo ^a   Tsuta, Koji ^a   Horinouchi, Hidehito ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Kubota, Kaoru ^a   Tamura, Tomohide ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Carboplatin; Paclitaxel; Thymic carcinoma

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CYTOLOGY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; THYMUS CANCER; THYMUS CARCINOMA; UNDIFFERENTIATED CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; RETROSPECTIVE STUDIES; THERAPEUTICS; THYMUS NEOPLASMS;

EID: 79961058814     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr089     Document Type: Article

References (20)

1. Weiss GJ. Thymic carcinoma: current and future therapeutic interventions. Expert Opin Investig Drugs 2010;19:1007-16.
2. Shimosato Y, Kameya T, Nagai K, Suemasu K. Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol 1977;1: 109-21.
3. Rosai J, Sobin L. Histological Typing of Tumours of the Thymus. Berlin: Springer; 1999.
4. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003;76:878-84; discussion 884-5.
5. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY. Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. Eur J Cardiothorac Surg 2009;36:159-62; discussion 163.
6. Koizumi T, Takabayashi Y, Yamagishi S, Tsushima K, Takamizawa A, Tsukadaira A, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002;25:266-8.
7. Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 2003;98:926-31.
8. Loehrer PJ, Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001;91:2010-5.
9. Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2000;1:1131-61.
10. Maruyama R, Suemitsu R, Okamoto T, Kojo M, Aoki Y, Wataya H, et al. Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. Oncology 2006;70:325-9.
11. Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010;67:194-7.
12. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011;29:2060-5.
13. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
15. Armitage P, Berry G, Matthews J. Survival analysis. In: Armitage P, Berry G, Matthews J, editors. Statistical Methods in Medical Research. 4th edn. Oxford: Blackwell Science 2002;568-90.
16. Lemma G, Loehrer P, Lee J, Langer C, Tester W, Johnson D. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008;26(Suppl):428s (abstr 8018).
17. Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-6.
18. Disel U, Oztuzcu S, Besen AA, Karadeniz C, Kose F, Sumbul AT, et al. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 2011;71:109-12.
19. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-5.
20. Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou-Strauss A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 2010;103:196-200.